A Look Into the CME Crystal Ball

We had some thought-provoking conversations with our CME colleagues at Alliance 2020. As we reflect on our takeaways from the conference, there's one underlying question that makes us hopeful, perplexed, and excited all at the same time. Our team at i3 Health wants to know… What will the future landscape of the CME industry look like? Here are some of the trends that we've picked up on from the musings of the CME community at Alliance 2020: 1.  Increasing standards for outcomes Everyth...

Continue reading

Collaboration Is the Key to Success in CME: Takeaways From MAACME 2019

i3 Health staff attended the 9th annual conference of the Mid-Atlantic Alliance for Continuing Medical Education (MAACME) last week in Harrisburg, PA. This year's conference featured interactive sessions facilitated by experienced CME thought leaders. Topics included updates from the ACCME, grant funding, best practices for needs assessments, evolving technology in education, and much more! This small-scale conference leaves a big impact for those in attendance. MAACME is a great place for us to...

Continue reading

Addressing Educational Needs in Castration-Resistant Prostate Cancer

With the substantial expansion of treatment options for castration-resistant prostate cancer (CRPC), including novel hormone therapies, second-generation taxanes, immunotherapy, and bone metastasis-targeted agents, there is a significant need for continuing medical education (CME) to ensure that physicians remain well informed as they seek to optimize treatment for their patients. Assessment data from i3 Health's CME-approved satellite symposium, Castration-Resistant Prostate Cancer: Implementin...

Continue reading

Oncology Nurses Share Their Favorite CNE Formats

i3 Health's surveys of oncology nurses at the Oncology Nursing Society (ONS) 44th Annual Congress in Anaheim, California, in April 2019 revealed respondents' preferred formats for continuing nursing education (CNE) activities. The surveys focused on educational needs concerning immune checkpoint inhibitors, cyclin-dependent kinase (CDK)4/6 inhibitors, chimeric antigen receptor (CAR) T-cell therapy, poly (ADP)-ribose polymerase (PARP) inhibitors, and biosimilars. Surveys were completed by 304 onc...

Continue reading


Stay up to date on accreditation news and best practices!

Follow Us

Copyright © i3 Health. All rights reserved.